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Abstract Fluconazole resistance occurs in > 10% of cases of 
candidosis during the late stages of AIDS. We show here in two 
clinical isolates that resistance was caused by defective sterol 
A5<6-desaturation. This altered the type of sterol accumulating 
under fluconazole treatment from 14a-methylergosta-8,24(28)-
dien-3ß,6a-diol to 14a-methylfecosterol which is capable of 
supporting growth. A consequence of this mechanism of azole 
resistance is that an absence of ergosterol causes cross-resistance 
to the other major antifungal agent available, amphotericin B. 
The results also show that growth arrest after fluconazole 
treatment of C. albicans in clinical conditions is caused by 14a-
methylergosta-8,24(28)-dien-3ß,6a-diol accumulation. 
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1. Introduction 
Azole antifungals have proved to be central to therapy for 
the rapidly increasing numbers of patients infected with fungi. 
Their mode of action is through inhibition of a cytochrome 
P450 enzyme (CYP51) which undertakes 14cc-demethylation 
of lanosterol in Saccharomyces cerevisiae, but 24-methylenedi-
hydrolanosterol in most other fungi including the major hu-
man pathogen Candida albicans (for review, see [1]). Plants 
and mammals also have an equivalent activity, but the anti-
fungals are selective inhibitors of the fungal enzyme. The con-
sequence of inhibition is a reduction in the intracellular levels 
of ergosterol, the main sterol of fungi, and an increase in 
substrate and other abnormal sterols produced by further me-
tabolism of the substrate, but without removal of the Ma-
methyl group. This change in sterol composition results in 
growth arrest. 
Resistance to azole antifungals (Fig. 1A) has been an im-
portant problem in agriculture among phytopathogens, but 
for fluconazole it has also become a considerable obstacle to 
successful therapy in late-stage AIDS patients as more than 
10% now develop mucosal candidosis resistant to fluconazole 
[2]. The best elucidated mechanism of azole resistance is from 
laboratory studies with S. cerevisiae where a change in sterol 
metabolism caused by mutation in sterol A5,6-desaturase 
causes resistance. The target enzyme was still inhibited, but 
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instead of accumulating 14a-methylergosta-8,24(28)-dien-
3ß,6a-diol (14a-methyl-3,6-diol), 14a-methylfecosterol was 
produced which fulfilled the requirements of the cell for 
growth unlike the 6-hydroxylated sterol (Fig. IB [3]). Sterol 
A5,6-desaturase mutations also act as suppressor mutations 
allowing viability of S. cerevisiae strains containing an other-
wise lethal gene disruption in CYP51 which subsequently also 
synthesise 14a-methylfecosterol [4]. Presumably, the retention 
of the 14a-methyl group in the sterol interferes with at-
tempted A5'6-desaturation in normal strains, resulting in 6-hy-
droxylation which is incompatible with sterol membrane func-
tion. Despite these S. cerevisiae studies, the general relevance 
of defective sterol A5,6-desaturase to azole antifungal resist-
ance in practical settings has remained unclear. 
Due to its therapeutic importance, a large effort is currently 
being made towards understanding the basis of resistance in 
C. albicans from the clinic. Reduced accumulation of drug has 
been observed in two clinical isolates [5] and altered levels of 
efflux pumps have been associated with resistance elsewhere, 
although without examining changes in sterol phenotype or 
target enzyme for azole drugs [6]. Considerable differences 
exist between laboratory cultures of S. cerevisiae and patho-
genic C. albicans infecting a human host which might alter the 
types of mutants selected e.g. regarding sterol A5,6-desaturase. 
C. albicans is diploid, necessitating a dominant mechanism to 
operate and the conditions of growth differ considerably 
which might affect the chances for survival of certain strains. 
For example, S. cerevisiae mutants defective in sterol A5,6-
desaturase are osmotically sensitive and are unable to grow 
on carbon sources requiring respiration, suggesting impaired 
mitochondrial function [7]. Despite these potential areas for 
difference we show here that this mechanism of resistance is 
present clinically in isolates from AIDS patients and can be 
expected at a high frequency. 
2. Materials and methods 
2.1. Strains 
All C. albicans isolates were from AIDS patients. SI and S2 were 
fluconazole-sensitive isolates of C. albicans, but Rl and R2 exhibited 
fluconazole resistance. Rl was from a 48 year old female, HIV posi-
tive, who had undergone fluconazole therapy at 100 mg/day rising to 
400 mg/day over several years. The therapy failed as did amphotericin 
B therapy at 30 mg/day. R2 was from a 36 year old male, HIV 
positive, receiving repetitive fluconazole therapy for several years 
whose last treatment was 6 weeks at up to 800 mg/day. All cultures 
used RPMI-1640 medium (Sigma), unless specified. 
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2.2. Chemicals 
Unless specified all chemicals were obtained from Sigma Chemical 
Company, Poole, Dorset, UK. 
2.3. Growth inhibition studies 
Stationary phase cells obtained from plate cultures incubated at 
37°C on RPMI-1640 medium with 2% (w/v) Difco Bactoagar were 
inoculated in 2 ml medium contained in 60 ml Sterilin containers at 
5000 cells/ml. Treatment with various doses of antifungal compound 
occurred over 3 days at 37°C, 150 rpm and growth was assessed by 
cell counts and colony-forming units/ml on YEPD consisting of 2% 
(w/v) glucose, 2% (w/v) Difco Bactopeptone, 1% (w/v) Difco yeast 
extract and 2% (w/v) Difco Bactoagar. Each test was repeated at least 
three times and minimum inhibitory concentrations (MIC) were con-
stant. Resistance of the strains was confirmed by E-test. 
2.4. Identification of sterols by GCIMS 
Samples for GC/MS were prepared from 50-ml cultures in the ex-
ponential phase of growth on RPMI-1650. Treated cells were exposed 
to fluconazole at 16 μ^ητΐ over 24 h (in excess of the MIC for sensi-
tive strains). The cell pellet was saponified in 15% (w/v) KOH in 90% 
(w/v) ethanol at 80°C for 1 h. Non-saponifiable lipids (sterols and 
sterol precursors) were extracted with 3X5 ml heptane and dried 
under nitrogen. Following silylation for 1 h at 60°C with BSTFA 
(50 μΐ) in 50 μΐ of toluene, sterols were analysed by GC/MS (VG 
12-250 (VG Biotech) using split injections with a split ratio of 20:1. 
Sterol identification was by reference to relative retention time and 
mass spectra as reported previously [4,5]. 
3. Results 
Fluconazole 
B 
AIOIM INHIBITION 
■x 
ergosta-7,22-dienoi 14a-meihylfeco£terol 
Table 1 shows the minimum inhibitory concentrations ob-
served for the clinical isolates of C. albicans when investigated 
in vitro. They exhibited a range of sensitivities with isolates 
Rl and R2 being resistant to fluconazole on comparison to SI 
and S2. Resistance to the other major antifungal drug ampho-
tericin B was also observed, although the -fold increase in 
resistance was not as high as between sensitive and resistant 
strains in the fluconazole treatments. 
Analysis of sterols present in the strains showed a clear 
difference between the sensitive strains SI and S2 and the 
resistant strains Rl and R2 (Table 2). The pattern of sterols 
in SI and S2 cells changed from predominantly ergosterol, 
when untreated, to containing a high concentration of 14a-
methyl-3,6-diol after treatment with fluconazole. Rl and R2 
were clearly defective in sterol A5,6-desaturation accumulating 
mainly ergosta-7-enol and also ergosta-7,22-dienol when un-
treated with fluconazole. R2 also accumulated ergosta-
7,24(28)-dienol, another sterol lacking A5,6-desaturation. Un-
der treatment they did not accumulate the 14<x-methyl-3,6-
diol, but instead formed the precursor 14a-methylfecosterol 
which allowed them to continue growing in the presence of 
the drug. The substrate of sterol 14oc-demethylase, 24-methyl-
enedihydrolansterol (eburicol) and its C4-demethylated deriv-
ative, obtusifolione also accumulated. 
Table 1 
Minimum inhibitory concentrations of fluconazole and amphotericin 
B observed on treating the various clinical isolates of Candida albi-
cans from AIDS patients 
C. albicans isolate Minimum inhibitory concentration (jig/ml) 
Fluconazole Amphotericin B 
SI 
S2 
Rl 
R2 
4.0 
5.0 
62.0 
78.0 
0.5 
1.0 
4.0 
4.5 
ergosterol 14a-methyl-3,6-dioi 
Fig. 1. (A) The structure of fluconazole and (B) the effect of fluco-
nazole inhibition of ergosterol biosynthesis in Saccharomyces cerevi-
siae. Structures included are lanosterol, the substrate of sterol 14a-
demethylase in this yeast; ergosta-7,22-dienol, a substrate for sterol 
Δ5'6-desaturase; ergosterol, the end-product of the pathway and, 
from azole treated cells, 14a-methylfecosterol and 14a-methylergos-
ta-8,24(28)-dien-3ß,6a-diol. 
4. Discussion 
The findings here indicate that defective sterol A5,6-desat-
uration is a common mechanism of fluconazole resistance in 
C. albicans from AIDS patients, being observed in both resist-
ant isolates analysed in this study. It also shows accumulation 
of 14oc-methyl-3,6-diol is responsible for growth arrest of this 
yeast following fluconazole treatment under clinical condi-
tions as avoiding its accumulation allows continued growth. 
Previously, we observed a partial dominance effect for fluco-
nazole resistance in a S. cerevisiae strain heterozygous for a 
sterol Δ5,6 -desaturase mutation [3] and this may suggest a 
possible route towards the development of the phenotype ob-
served here for the C. albicans strains Rl and R2. Initially, a 
resistance mutation may have been selected in one of the two 
alíeles and subsequently gene conversion or further mutation 
involving the second alíele could produce increased resistance 
in a daughter strain exposed over a prolonged period of treat-
ment to fluconazole. Further analysis of the genes in the re-
sistant strains will cast light on the origin of the defective 
alíeles in these diploid pathogenic C. albicans. The absence 
of ergosterol in the resistant strains Rl and R2 can be attrib-
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Table 2 
Percentage composition 
Sterol 
of various sterols of the C. 
C. 
albicans clinical isolates with and without treatment with 16 
albicans isolate 
Without treatment 
SI S2 Rl R2 
Following 
SI 
μg/ml fluconazole 
fluconazole treatment 
S2 R l R2 
Ergosterol 
Ergosta-7,24(28)-dienol 
Ergosta-7,22-dienol 
Ergosta-7-enol 
Euburicol 
Obtusifoliol 
14a-Methylfecosterol 
14a-Methyl-3,6-diol 
Unknown 
98.0 97.0 
2.0 3.0 
77.0 
22.0 
1.0 
11.0 
74.0 
12.0 
3.0 
2.0 
16.1 
34.5 
45.2 
2.2 
1.6 
12.3 
13.1 
72.0 
1.0 
7.0 
10.0 
82.0 
1.0 
12.0 
14.0 
71.0 
3.0 
uted as the cause of their cross-resistance to amphotericin B, 
as it is known that this polyene antibiotic acts through bind-
ing to ergosterol [8]. The medical implications of these obser-
vations are also discussed elsewhere [9]. 
The relative frequency of this mechanism of resistance 
among other potential mechanisms remains to be determined 
and in two other strains we analysed previously it did not 
operate; instead reduced intracellular accumulation of drug 
was observed and normal sterol biosynthesis [5]. The disturb-
ing prospect of significant numbers of resistant strains being 
cross-resistant to amphotericin B as observed here is alarming 
and underlines the requirement for new antifungals with dif-
ferent modes of action. Additionally, there is a need for a 
survey of molecular mechanisms of resistance in order to de-
termine the best therapeutic response. 
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